Samuel L Aitken1, M Jahangir Alam1, Mohammed Khaleduzzaman, Mohammed Khaleduzzuman1, Seth T Walk2, William L Musick3, Vy P Pham4, Jennifer L Christensen5, Robert L Atmar6, Yang Xie7, Kevin W Garey1. 1. 1Department of Pharmacy Practice and Translational Research,University of Houston College of Pharmacy,Houston,Texas. 2. 3Department of Microbiology and Immunology,Montana State University,Bozeman,Montana. 3. 2Department of Pharmacy,Houston Methodist Hospital,Houston,Texas. 4. 4Department of Pharmacy,Memorial Hermann Northwest Hospital,Houston,Texas. 5. 5Department of Internal Medicine,Baylor College of Medicine Houston,Texas. 6. 6Department of Medicine,Section of Infectious Disease,Baylor College of Medicine Houston,Texas. 7. 7Merck & Co.,Whitehouse Station,New Jersey.
Abstract
BACKGROUND: Conflicting reports have been published on the association between Clostridium difficile ribotypes and severe disease outcomes in patients with C. difficile infection (CDI); several so-called hypervirulent ribotypes have been described. We performed a multicenter study to assess severe disease presentation and severe outcomes among CDI patients infected with different ribotypes. METHODS: Stool samples that tested positive for C. difficile toxin were collected and cultured from patients who presented to any of 7 different hospitals in Houston, Texas (2011-2013). C. difficile was characterized using a fluorescent PCR ribotyping method. Medical records were reviewed to determine clinical characteristics and ribotype association with severe CDI presentation (ie, leukocytosis and/or hypoalbuminemia) and severe CDI outcomes (ie, ICU admission, ileus, toxic megacolon, colectomy, and/or in-hospital death). RESULTS: Our study included 715 patients aged 61±18 years (female: 63%; median Charlson comorbidity index: 2.5±2.4; hospital-onset CDI: 45%; severe CDI: 36.7%; severe CDI outcomes: 12.3%). The most common ribotypes were 027, 014-020, FP311, 002, 078-126, and 001. Ribotype 027 was a significant independent predictor of severe disease (adjusted odds ratio [aOR], 2.24; 95% confidence interval [CI], 1.53-3.29; P<.001) and severe CDI outcomes (aOR, 1.71; 95% CI, 1.02-2.85; P=.041) compared with all other ribotypes in aggregate. However, in an analysis using all common ribotypes as individual variables, ribotype 027 was not associated with severe CDI outcomes more often than other ribotypes. CONCLUSION: Ribotype 027 showed virulence equal to that of other ribotypes identified in this endemic setting. Clinical severity markers of CDI may be more predictive of severe CDI outcomes than a particular ribotype.
BACKGROUND: Conflicting reports have been published on the association between Clostridium difficile ribotypes and severe disease outcomes in patients with C. difficileinfection (CDI); several so-called hypervirulent ribotypes have been described. We performed a multicenter study to assess severe disease presentation and severe outcomes among CDIpatients infected with different ribotypes. METHODS: Stool samples that tested positive for C. difficile toxin were collected and cultured from patients who presented to any of 7 different hospitals in Houston, Texas (2011-2013). C. difficile was characterized using a fluorescent PCR ribotyping method. Medical records were reviewed to determine clinical characteristics and ribotype association with severe CDI presentation (ie, leukocytosis and/or hypoalbuminemia) and severe CDI outcomes (ie, ICU admission, ileus, toxic megacolon, colectomy, and/or in-hospital death). RESULTS: Our study included 715 patients aged 61±18 years (female: 63%; median Charlson comorbidity index: 2.5±2.4; hospital-onset CDI: 45%; severe CDI: 36.7%; severe CDI outcomes: 12.3%). The most common ribotypes were 027, 014-020, FP311, 002, 078-126, and 001. Ribotype 027 was a significant independent predictor of severe disease (adjusted odds ratio [aOR], 2.24; 95% confidence interval [CI], 1.53-3.29; P<.001) and severe CDI outcomes (aOR, 1.71; 95% CI, 1.02-2.85; P=.041) compared with all other ribotypes in aggregate. However, in an analysis using all common ribotypes as individual variables, ribotype 027 was not associated with severe CDI outcomes more often than other ribotypes. CONCLUSION: Ribotype 027 showed virulence equal to that of other ribotypes identified in this endemic setting. Clinical severity markers of CDI may be more predictive of severe CDI outcomes than a particular ribotype.
Authors: Jonathan N V Martinson; Susan Broadaway; Egan Lohman; Christina Johnson; M Jahangir Alam; Mohammed Khaleduzzaman; Kevin W Garey; Jessica Schlackman; Vincent B Young; Kavitha Santhosh; Krishna Rao; Robert H Lyons; Seth T Walk Journal: J Clin Microbiol Date: 2015-01-28 Impact factor: 5.948
Authors: Isaac See; Yi Mu; Jessica Cohen; Zintars G Beldavs; Lisa G Winston; Ghinwa Dumyati; Stacy Holzbauer; John Dunn; Monica M Farley; Carol Lyons; Helen Johnston; Erin Phipps; Rebecca Perlmutter; Lydia Anderson; Dale N Gerding; Fernanda C Lessa Journal: Clin Infect Dis Date: 2014-03-05 Impact factor: 9.079
Authors: Seth T Walk; Dejan Micic; Ruchika Jain; Eugene S Lo; Itishree Trivedi; Eugene W Liu; Luay M Almassalha; Sarah A Ewing; Cathrin Ring; Andrzej T Galecki; Mary A M Rogers; Laraine Washer; Duane W Newton; Preeti N Malani; Vincent B Young; David M Aronoff Journal: Clin Infect Dis Date: 2012-09-12 Impact factor: 9.079
Authors: Mark Miller; Denise Gravel; Michael Mulvey; Geoffrey Taylor; David Boyd; Andrew Simor; Michael Gardam; Allison McGeer; James Hutchinson; Dorothy Moore; Sharon Kelly Journal: Clin Infect Dis Date: 2010-01-15 Impact factor: 9.079
Authors: Stuart Johnson; Thomas J Louie; Dale N Gerding; Oliver A Cornely; Scott Chasan-Taber; David Fitts; Steven P Gelone; Colin Broom; David M Davidson Journal: Clin Infect Dis Date: 2014-05-05 Impact factor: 9.079
Authors: A Sarah Walker; David W Eyre; David H Wyllie; Kate E Dingle; David Griffiths; Brian Shine; Sarah Oakley; Lily O'Connor; John Finney; Alison Vaughan; Derrick W Crook; Mark H Wilcox; Tim E A Peto Journal: Clin Infect Dis Date: 2013-03-05 Impact factor: 20.999
Authors: Bradley Endres; Eugénie Bassères; Tasnuva Rashid; Long Chang; M Jahangir Alam; Kevin W Garey Journal: J Vis Exp Date: 2017-05-25 Impact factor: 1.355
Authors: Masaad Saeed Almutairi; Anne J Gonzales-Luna; Faris S Alnezary; Saad B Fallatah; M Jahangir Alam; Khurshida Begum; Kevin W Garey Journal: Anaerobe Date: 2021-08-27 Impact factor: 3.331
Authors: Kelly R Reveles; Kierra M Dotson; Anne Gonzales-Luna; Dhara Surati; Bradley T Endres; M Jahangir Alam; Kevin W Garey Journal: Clin Infect Dis Date: 2019-05-17 Impact factor: 9.079
Authors: Mairéad Connor; Padrig B Flynn; Derek J Fairley; Nikki Marks; Panagiotis Manesiotis; William G Graham; Brendan F Gilmore; John W McGrath Journal: Sci Rep Date: 2017-02-03 Impact factor: 4.379